Published in Nat Rev Cancer on April 01, 2004
Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | NCT00540007
Ribosomopathies: human disorders of ribosome dysfunction. Blood (2010) 4.43
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood (2011) 3.58
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48
T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res (2012) 2.43
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A (2007) 2.39
DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science (2015) 2.29
Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature (2014) 2.11
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med (2015) 2.10
Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin (2010) 1.98
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med (2008) 1.97
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol (2009) 1.88
Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood (2006) 1.88
Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol (2008) 1.83
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol (2009) 1.64
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res (2013) 1.61
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood (2011) 1.58
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors. Blood (2015) 1.51
The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol (2012) 1.44
Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J (2005) 1.33
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog (2011) 1.29
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol (2008) 1.25
Secondary primary malignancies in multiple myeloma: an old NEMESIS revisited. Adv Hematol (2012) 1.24
NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets (2008) 1.16
Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest (2014) 1.13
Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J Mol Med (Berl) (2012) 1.12
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09
Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS. PLoS One (2010) 1.09
Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther (2009) 1.09
Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol (2011) 1.08
Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol (2008) 1.07
Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood (2006) 1.06
Tautomerism in drug discovery. J Comput Aided Mol Des (2010) 1.05
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. J Transl Med (2007) 1.02
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J (2013) 1.01
Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer (2005) 1.01
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res (2008) 1.01
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res (2013) 1.00
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol (2006) 1.00
Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol (2009) 0.99
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica (2009) 0.99
Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome. Semin Hematol (2011) 0.98
Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis (2010) 0.96
Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Nature (2016) 0.95
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica (2013) 0.94
New sources of drugs for hematologic malignancies. Blood (2011) 0.93
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.92
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer (2009) 0.92
Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov (2007) 0.92
Novel molecular pathways in Gorham disease: implications for treatment. Pediatr Blood Cancer (2013) 0.91
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia (2011) 0.90
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother (2013) 0.89
Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget (2014) 0.89
Regulating the Regulators: Recent Revelations in the Control of E3 Ubiquitin Ligases. J Biol Chem (2015) 0.89
Novel immune modulators used in hematology: impact on NK cells. Front Immunol (2013) 0.89
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid (2010) 0.89
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol (2013) 0.89
Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res (2012) 0.88
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. Acta Biochim Biophys Sin (Shanghai) (2013) 0.88
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion. Haematologica (2010) 0.87
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. Invest New Drugs (2006) 0.86
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag (2008) 0.86
Primary cutaneous lymphomas: diagnosis and treatment. Postepy Dermatol Alergol (2015) 0.84
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. J Oncol (2010) 0.84
Thalidomide-a notorious sedative to a wonder anticancer drug. Curr Med Chem (2013) 0.83
SPLINTS: small-molecule protein ligand interface stabilizers. Curr Opin Struct Biol (2016) 0.82
Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol (2009) 0.82
Treatment of pediatric refractory Crohn's disease with thalidomide. World J Gastroenterol (2011) 0.81
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80
Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells. Oncol Lett (2012) 0.80
Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget (2016) 0.80
No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers. Cancer Chemother Pharmacol (2014) 0.79
Important genes in the pathogenesis of 5q- syndrome and their connection with ribosomal stress and the innate immune system pathway. Leuk Res Treatment (2012) 0.79
Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Exp Neurol (2015) 0.79
Future directions in castrate-resistant prostate cancer therapy. Clin Genitourin Cancer (2010) 0.79
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica (2009) 0.79
[Individualized management and therapy of myelodysplastic syndromes]. Wien Klin Wochenschr (2008) 0.78
Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol (2014) 0.78
Pomalidomide suppresses cerulein-induced acute pancreatitis in mice. J Gastroenterol (2011) 0.78
Inhibition of endothelial Slit2/Robo1 signaling by thalidomide restrains angiogenesis by blocking the PI3K/Akt pathway. Dig Dis Sci (2014) 0.78
Targeted therapy in the treatment of malignant gliomas. Onco Targets Ther (2009) 0.78
Myelodysplastic syndromes--many new drugs, little therapeutic progress. Mayo Clin Proc (2010) 0.78
Drug Repurposing for Cancer Therapy. J Cancer Sci Ther (2012) 0.78
Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol (2014) 0.78
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clin Cancer Res (2016) 0.78
Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. Cell Rep (2015) 0.77
Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma. Genes Cancer (2014) 0.77
Overcoming obstacles to repurposing for neurodegenerative disease. Ann Clin Transl Neurol (2014) 0.77
Vaccines versus immunotherapy: overview of approaches in deciding between options. Hum Vaccin Immunother (2014) 0.77
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother (2008) 2.21
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood (2012) 1.71
HIV immunopathogenesis and strategies for intervention. Lancet Infect Dis (2008) 1.67
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res (2005) 1.52
Origins of HIV and the evolution of resistance to AIDS. Science (2006) 1.49
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol (2002) 1.35
PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost (2007) 1.24
Impact of surgery on immunologic function: comparison between minimally invasive techniques and conventional laparotomy for surgical resection of colorectal tumors. Am J Surg (2008) 1.10
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int (2004) 1.06
Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide. Anticancer Res (2011) 1.06
Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother (2002) 1.05
PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther (2013) 1.01
Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem (2012) 0.98
Doxycycline induces caspase-dependent apoptosis in human pancreatic cancer cells. Int J Cancer (2007) 0.97
Recent advances and developments in treatment strategies against pancreatic cancer. Curr Clin Pharmacol (2009) 0.92
Possession of human leucocyte antigen DQ6 alleles and the rate of CD4 T-cell decline in human immunodeficiency virus-1 infection. Immunology (2004) 0.92
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One (2012) 0.91
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Immunology (2013) 0.91
Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy. Cancer Immunol Immunother (2011) 0.91
Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. J Med Chem (2010) 0.90
Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opin Biol Ther (2004) 0.87
A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Mol Biol Rep (2009) 0.87
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int J Cancer (2010) 0.86
Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines. Mol Carcinog (2011) 0.85
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues. FEBS Open Bio (2013) 0.84
Investigation of the mechanisms by which EB1089 abrogates apoptosis induced by 9-cis retinoic acid in pancreatic cancer cells. Pancreas (2006) 0.84
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res (2003) 0.83
The gene expression profile of unstimulated dendritic cells can be used as a predictor of function. Int J Cancer (2011) 0.82
In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother Pharmacol (2010) 0.81
Recent developments in antiangiogenic therapy. Expert Opin Biol Ther (2002) 0.80
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer (2009) 0.80
Pathogenesis of HIV: non-specific immune hyperactivity and its implications for vaccines. Clin Med (2008) 0.80
Rationale for combining immunotherapy with chemotherapy. Immunotherapy (2015) 0.79
Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs (2003) 0.79
Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol (2002) 0.79
HIV induced AIDS and related cancers: chronic immune activation and future therapeutic strategies. Adv Cancer Res (2008) 0.79
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents. Curr Drug Targets Immune Endocr Metabol Disord (2003) 0.78
HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. AIDS Res Hum Retroviruses (2008) 0.78
Tripartite immune cell co-operation in the Bacillus Calmette Guérin-induced activation of γδ T cells. Immunol Cell Biol (2013) 0.78
Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol Rep (2003) 0.78
MTT assays can underestimate cell numbers. Cancer Chemother Pharmacol (2009) 0.78
Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest (2015) 0.77
Dendritic cell immunotherapy for melanoma. Rev Recent Clin Trials (2006) 0.77
Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells. Pancreas (2009) 0.77
Angiogenesis inhibitors in cancer therapy. Curr Opin Investig Drugs (2003) 0.77
Cannabis-derived substances in cancer therapy--an emerging anti-inflammatory role for the cannabinoids. Curr Clin Pharmacol (2010) 0.77
The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer Immunol Immunother (2005) 0.77
Successful live cell harvest from bisected sentinel lymph nodes research report. J Immunol Methods (2004) 0.76
Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity. Cancer Immunol Immunother (2003) 0.76
Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma. Hum Vaccin Immunother (2013) 0.76
The potential beneficial effects of drugs on the immune response to vaccination. Semin Oncol (2012) 0.76
Zoledronic acid causes γδ T cells to target monocytes and down-modulate inflammatory homing. Immunology (2014) 0.76
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Med Oncol (2009) 0.76
The power of the web in cancer drug discovery and clinical trial design: research without a laboratory? Cancer Inform (2010) 0.75
Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target? Future Oncol (2012) 0.75
Immunotherapy and the development of cancer vaccines. Expert Rev Vaccines (2006) 0.75
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer. Br J Cancer (2016) 0.75
Human Peritoneal Mesothelial Cells Display Phagocytic and Antigen-Presenting Functions to Contribute to Intraperitoneal Immunity. Int J Gynecol Cancer (2016) 0.75
Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study). Cancer Immunol Immunother (2013) 0.75